Single Drug Polyestradiol Phosphate Therapy in Pro static Cancer

  title={Single Drug Polyestradiol Phosphate Therapy in Pro static Cancer},
  author={R. Stege and K. Carlstr{\"o}m and L. Collste and A. Eriksson and P. Henriksson and A. Pousette},
  journal={American Journal of Clinical Oncology},
  • R. Stege, K. Carlström, +3 authors A. Pousette
  • Published 1988
  • Medicine
  • American Journal of Clinical Oncology
  • Serum concentrations of testosterone (T) and estradiol-17β (E2) were analyzed in prostatic cancer patients treated with 160, 240, or 320 mg polyestradiol phosphate (PEP) i.m. every fourth week as single drug therapy during a 6 month period. Estrogen effects on the liver were studied by analyzing serum levels of sex hormone binding globulin (SHBG) in the 320 mg group and compared with values obtained in patients treated with 80 mg PEP i.m. every fourth week + oral ethinylestradiol (EE2) 150 μg… CONTINUE READING
    26 Citations